Bill-AxelsonAHolmbergLFilenFRadical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst2008; 100 (August): 1144-54.
3.
SchroderFHHugossonJRoobolMJScreening and prostate-cancer mortality in a randomized European study. N Engl J Med2009; 360 (March): 1320-8.
4.
NealDEDonovanJLMartinRMHamdyFC. Screening for prostate cancer remains controversial. Lancet2009;(August).
5.
EelesRAKote-JaraiZGilesGGMultiple newly identified loci associated with prostate cancer susceptibility. Nat Genet2008; 40 (March): 316-21.
TomlinsSALaxmanBDhanasekaranSMDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature2007; 448 (August): 595-9.
8.
CutressMLWhitakerHCMillsIGStewartMNealDE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci2008; 121 (April): 957-68.
9.
MassieCEAdryanBBarbosa-MoraisNLNew androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep2007; 8 (September): 871-8.
10.
TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer. Science2009; 324 (May): 787-90.
11.
AttardGReidAHA'HernRSelective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol2009; 27 (August): 3742-8.
12.
DonovanJMillsNSmithMQuality improvement report — Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Br Med J2002; 325 (October): 766-9.
13.
ParkerCClarkeNLogueJRADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol)2007; 19 (April): 167-71.
14.
CochraneAL. Random reflections on health services. London: RSM Press; 2007.
WiltTJ. Commentary: controversies in NICE guidance on prostate cancer. BMJ2008; 336 (March): 612-4.
17.
NHS. Urology Informed Decision Making Project. 2009 [cited; Available from:].
18.
D'AmicoAVWhittingtonRMalkowiczSBBiochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer2002; 95 (July): 281-6.
19.
NealDE. Can we accurately identify men with low risk prostate cancer?J Urol2008;180 (October): 1217-8.
20.
TaylorLGCanfieldSEDuXL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer2009; 115 (June): 2388-99.
21.
FallKGarmoHAndrenOProstate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst2007; 99 (April): 526-32.
22.
CuzickJFisherGKattanMWLong-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer2006; 95 (November): 1186-94.
23.
LobergRDFielhauerJRPientaBAProstate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology2003; 62 (Suppl. 1 (December)): 128-33.
24.
LoblawDAVirgoKSNamRInitial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2007; 25 (April): 1596-605.
25.
VickersAJSavageCO'BrienMFLiljaH. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol2009; 27 (January): 398-403.
26.
O'BrienMFCroninAMFearnPAPretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol2009; 27 (August): 3591-7.
27.
MetcalfeCTillingKDavisMCurrent strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. Br J Cancer2009; 101 (August): 390-4.
